This content requires a premium subscription.
Please
log in
or
subscribe
to continue.
JACC Specialty Journals
JACC: CardioOncology - Dual Angiotensin Receptor Neprilysin Inhibition with Sacubitril/Valsartan Attenuates Systolic Dysfunction in Experimental Doxorubicin-induced Cardiotoxicity
Released: Dec 15, 2020
Commentary by Dr. Virginia Hahn
JACC: CardioOncology - Dual Angiotensin Receptor Neprilysin Inhibition with Sacubitril/Valsartan Attenuates Systolic Dysfunction in Experimental Doxorubicin-induced Cardiotoxicity
00:00:00
